10 results about "Synovitis" patented technology

The application discloses a multi-component synovitis treatment composition based on repairing cartilage tissue and application thereof, and relates to the technical field of biological medicine, and the composition is composed of glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone and graded molecular weight sodium hyaluronate; the application precisely compounding the graded molecular weight sodium hyaluronate with the glucosamine hydrochloride, the chondroitin sulfate and the dimethyl sulfone according to weight parts, constructs a gradient slow-release and target delivery system of synovitis lesions, specifically inhibits the activity of hyaluronidase in the inflammatory joint cavity by using the dimethyl sulfone, greatly reduces the degradation of the sodium hyaluronate, prolongs the residence time of the active ingredients at the lesion site, realizes immediate analgesia and relieves joint stiffness by quickly forming a lubricating protective film by the high molecular weight sodium hyaluronate, the medium and low molecular weight sodium hyaluronate penetrates the synovial membrane barrier and carries the cartilage repair components to enrich in the cartilage defect area, and the synergistic effect of the components is realized.

The application provides a construction method and a content determination method of a synovitis preparation characteristic spectrum, and belongs to the technical field of drug detection. The construction method is that a test sample solution is prepared by using the synovitis preparation, then acetonitrile-0.08-0.12wt% formic acid aqueous solution is used as a mobile phase, high performance liquid chromatography detection is carried out, the characteristic spectrum of the synovitis preparation is obtained, and the content of components in the synovitis preparation is further determined. The method can comprehensively cover the key active components of core medicinal materials in the prescription of the synovitis preparation, realizes the synchronous detection of multiple categories and multiple target components, and completely solves the defects of single quality control index and incomplete coverage in the prior art.

This invention relates to the field of traditional Chinese medicine preparations, and discloses a Tongli capsule and its preparation process, comprising the following raw materials: Eupolyphaga sinensis, processed Arisaema heterophyllum, vinegar-processed frankincense, vinegar-processed myrrh, dragon bone, Angelica dahurica, Lysimachia christinae, safflower, Notopterygium incisum, Angelica sinensis, Saposhnikovia divaricata, Cimicifuga foetida, Ligusticum chuanxiong, and Acorus tatarinowii; wherein, the raw materials are dried, pulverized, mixed, and then filled into capsule shells to form capsules. This Tongli capsule, using a total of fourteen traditional Chinese medicines as raw materials, follows the treatment principles of traditional Chinese medicine of dispelling wind and dampness, relaxing muscles and tendons, and promoting blood circulation and removing blood stasis. It has significant efficacy for late-stage fractures and joint dislocations, joint pain, synovitis, and other diseases caused by wind-cold-dampness obstructing the meridians. Furthermore, the capsule dosage form, with its uniform fine powder contents, makes it convenient to take, provides accurate dosage, has high bioavailability, and improves patient compliance. Compared to decoctions, capsules do not require decocting, making them easier to carry and store; compared to pills and powders, capsules can mask unpleasant odors of the medicine, and disintegrate rapidly, resulting in faster onset of action.

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.

This invention discloses a neutralizing nanobody targeting soluble interleukin-17 receptor D (sIL-17RD), its preparation method, and its applications. The heavy chain variable region (VHH) of this nanobody contains a heavy chain complementarity-determining region 3 (CDR-H3) that specifically binds to sIL-17RD, with a length of 10 amino acids and containing 2–6 lysine residues. This invention provides four nanobodies: CQ5, CQ13, CQ11, and CQ6, corresponding to well-defined CDR-H1, CDR-H2, and CDR-H3 sequence combinations. This nanobody can specifically bind to and neutralize the biological activity of sIL-17RD, reducing chondrocyte death, promoting proliferation, and maintaining extracellular matrix homeostasis by inhibiting the P2rx7-NLRP3 inflammasome-mediated chondrocyte pyroptosis pathway. This invention also protects the nucleic acid encoding this nanobody, the recombinant expression vector, the host cell, the pharmaceutical composition, and the preparation method. The nanobodies described can be used to prepare drugs for the prevention and treatment of inflammatory osteoarthritis and other osteoarthritis. They can inhibit synovitis, reverse cartilage and subchondral bone degeneration, and relieve pain, showing promising application prospects.

The present invention discloses a multi-component synovitis therapeutic composition based on cartilage tissue repair and a use thereof, relating to the technical field of biomedicine. The composition comprises glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone, and graded molecular weight sodium hyaluronate. By compounding these components in precise parts by weight, the present invention constructs a gradient sustained-release and targeted delivery system for synovitis lesions. Dimethyl sulfone specifically inhibits hyaluronidase activity in the inflamed joint cavity, significantly reducing sodium hyaluronate degradation and prolonging the retention time of each active ingredient at the lesion site. High molecular weight sodium hyaluronate rapidly forms a lubricating protective film to achieve immediate analgesia and relieve ankylosis, while medium- and low-molecular-weight sodium hyaluronate penetrates the synovial barrier and carries cartilage repair components to the cartilage defect area, thereby achieving synergistic enhancement and comprehensively improving synovitis treatment efficacy.

This invention discloses a CH@SHP099-NPs composite hydrogel, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the technical challenge of achieving long-term, safe, and precise metabolic intervention with SHP2, this invention constructs a hydrogel system composed of chondroitin sulfate and hyaluronic acid. This system can retain SHP099-loaded nanoparticles within the joint cavity, forming a long-acting intrasynovial drug library, thereby continuously inhibiting the SHP2-AMPK signaling axis. The CH@SHP099-NPs composite hydrogel prepared in this invention can effectively reprogram the metabolic state of macrophages, reduce glycolysis flux, restore synovial immune metabolic homeostasis, and significantly improve synovial inflammation, chondrocyte activity, and cartilage structural integrity in vivo. This invention proposes a mechanism-guided local delivery metabolic intervention strategy, which is expected to provide a new interventional approach for the treatment of osteoarthritis.

This invention discloses a traditional Chinese medicine composition, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition comprises the following components in parts by weight: 30-60 parts Astragalus membranaceus granules, 20-40 parts Polygonum cuspidatum granules, 20-40 parts Spatholobus suberectus granules, 20-40 parts Caulis Clematis chinensis granules, 15-30 parts Corydalis yanhusuo granules, and 5-10 parts Asarum sieboldii granules. The traditional Chinese medicine composition of this invention uses Astragalus membranaceus granules as the principal ingredient, Polygonum cuspidatum granules as the assistant ingredient, and Spatholobus suberectus granules, Caulis Clematis chinensis granules, Corydalis yanhusuo granules, and Asarum sieboldii granules as adjuvant ingredients. These ingredients work synergistically to achieve the effects of invigorating qi and nourishing blood, relaxing muscles and tendons, promoting blood circulation and relieving pain. It has good efficacy and high safety in treating post-traumatic ankle arthritis, synovitis, and phlegm-blood stasis obstruction.

Disclosed herein are methods of treating or preventing rheumatoid arthritis by administering a syndecan-1 inhibitor or a synthenin-1 inhibitor capable of preventing syndecan-1 from binding to the PDZ-2 domain of syntenin-1. Also disclosed herein are methods of reducing or ameliorating one or more symptoms of rheumatoid arthritis, reducing syntenin-1 or syndecan-1 in synovial fluid or blood, reducing synovial inflammation, reducing cartilage degradation, reducing one or more inflammatory interferon transcription factors, reducing one or more monokines, reducing expression of one or more glycolytic factors, or increasing expression of one or more oxidative intermediates or enzymes in a subject.